UroGen Pharma Ltd (NASDAQ: URGN) kicked off on Monday, down -4.84% from the previous trading day, before settling in for the closing price of $19.44. Over the past 52 weeks, URGN has traded in a range of $3.42-$21.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 10.39% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -3.44%. With a float of $39.55 million, this company’s outstanding shares have now reached $46.20 million.
In an organization with 235 employees, it is important to assess its efficiency.
UroGen Pharma Ltd (URGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of UroGen Pharma Ltd is 14.51%, while institutional ownership is 92.29%. The most recent insider transaction that took place on Aug 11 ’25, was worth 176,900. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $17.69, taking the stock ownership to the 148,229 shares. Before that another transaction happened on Jul 28 ’25, when Company’s General Counsel sold 7,522 for $19.14, making the entire transaction worth $143,971. This insider now owns 41,492 shares in total.
UroGen Pharma Ltd (URGN) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.55 earnings per share (EPS), higher than consensus estimate (set at -0.82) by 0.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.44% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
Take a look at UroGen Pharma Ltd’s (URGN) current performance indicators. Last quarter, stock had a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.32, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -1.03 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was inferior than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.04%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 85.71%, which indicates a significant increase from 41.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.18 in the past 14 days, which was higher than the 1.03 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.55, while its 200-day Moving Average is $11.84. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $19.24. Second resistance stands at $19.99. The third major resistance level sits at $20.40. If the price goes on to break the first support level at $18.08, it is likely to go to the next support level at $17.67. The third support level lies at $16.92 if the price breaches the second support level.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
The company with the Market Capitalisation of 855.81 million has total of 46,264K Shares Outstanding. Its annual sales at the moment are 90,400 K in contrast with the sum of -126,870 K annual income. Company’s last quarter sales were recorded 24,220 K and last quarter income was -49,940 K.
